Blockade of IL-6 trans signaling attenuates pulmonary fibrosis

Journal of Immunology

Volumn 193, Issue 7, 2014, Pages 3755-3768

  Le Thanh Thuy, T ^a,b   Karmouty Quintana, Harry ^a   Melicoff, Ernestina ^c   Le Thanh Truc, T ^a   Weng, Tingting ^a   Chen, Ning Yuan ^a   Pedroza, Mesias ^a,b,c   Zhou, Yang ^a   Davies, Jonathan ^c   Philip, Kemly ^a   Molina, Jose ^a   Luo, Fayong ^a   George, Anuh T ^c   Garcia Morales, Luis J ^d   Bunge, Raquel R ^d   Bruckner, Brian A ^d   Loebe, Matthias ^d   Seethamraju, Harish ^d   Agarwal, Sandeep K ^c   Blackburn, Michael R ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM17 PROTEIN; COLLAGEN; CYTOKINE RECEPTOR ANTAGONIST; FIBRONECTIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT GP130FC; SCLEROPROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN; IL6R PROTEIN, HUMAN; INTERLEUKIN 6 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FIBROBLAST; FIBROSING ALVEOLITIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; MALE; MOUSE; MYOFIBROBLAST; NONHUMAN; OXYGEN SATURATION; PNEUMONIA; SIGNAL TRANSDUCTION; ANIMAL; CLINICAL TRIAL; DISEASE MODEL; FEMALE; GENETICS; IMMUNOLOGY; LUNG; LUNG FIBROSIS; MORTALITY; PATHOLOGY;

ANIMALS; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBRONECTINS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INTERLEUKIN-6; LUNG; MACROPHAGES, ALVEOLAR; MALE; MICE; MYOFIBROBLASTS; PULMONARY FIBROSIS; RECEPTORS, INTERLEUKIN-6; SIGNAL TRANSDUCTION;

EID: 84907222985     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1302470     Document Type: Article

References (75)

1. King, T. E., Jr., A. Pardo, and M. Selman. 2011. Idiopathic pulmonary fibrosis. Lancet 378: 1949- 1961.
2. Wynn, T. A. 2011. Integrating mechanisms of pulmonary fibrosis. J. Exp. Med. 208: 1339-1350.
3. Raghu, G., H. R. Collard, J. J. Egan, F. J. Martinez, J. Behr, K. K. Brown, T. V. Colby, J. F. Cordier, K. R. Flaherty, J. A. Las ky, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183: 788-824.
4. Altekruse, S. F., M. Krapcho, N. Neyman, R. Aminou, W. Waldron, J. Ruhl, N. Howlader, Z. Tatalovich, H. Cho, A. Mariotto, et al. 2010. SEER Cancer Statistics Revie w, 1975-2007. National Cancer Institute, Bethesda, MD.
5. Olson, A. L., J. J. Swigris, D. C. Lezotte, J. M. Norris, C. G. Wilson, and K. K. Brown. 2007. Mortality from pulmonary fibrosis i ncreased in the United States from 1992 to 2003. Am. J. Respir. Crit. Care Med. 176: 277-284.
6. Raghu, G., D. Weycker, J. Edelsberg, W. Z. Bradford, and G. Oster. 2006. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 174: 810-816.
7. Pedroza, M., D. J. Schneider, H. Karmouty-Quintana, J. Coote, S. Shaw, R. Corrigan, J. G. Molina, J. L. Alcorn, D. Galas, R. Gelinas, and M. R. Blackburn. 2011. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS ONE 6: e22667.
8. Zhou, Y., J. N. Murthy, D. Zeng, L. Belardinelli, and M. R. Blackburn. 2010. Alterations in adenosine metabolism and signaling in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. PLoS ONE 5: e9224.
9. Bauer, J., T. M. Bauer, T. Kalb, T. Taga, G. Lengyel, T. Hirano, T. Kishimoto, G. Acs, L. Mayer, and W. Gerok. 1989. Regulation of interleukin 6 receptor expression in human monocytes and monocyte-deri ved macrophages. Comparison with the expression in human hepatocytes. J. Exp. Med. 170: 1537-1549.
10. Chalaris, A., C. Garbers, B. Rabe, S. Rose-John, and J. Scheller. 2011. The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur. J. Cell Biol. 90: 484-494.
11. Jones, S. A., J. Scheller, and S. Rose-John. 2011. Therapeu tic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 121: 3375-3383.
12. Taga, T., Y. Kawanishi, R. R. Hardy, T. Hirano, and T. Kishimoto. 1987. Receptors for B cell stimulatory factor 2. Quantitation, specificity, distribution, and regulation of their expression. J. Exp. Med. 166: 967-981.
13. Scheller, J., A. Chalaris, D. Schmidt-Arras, and S. Rose-John. 2011. The proand anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813: 878-888.
14. Taga, T., M. Hibi, Y. Hirata, K. Yamasaki, K. Yasukawa, T. Matsuda, T. Hirano, and T. Kishimoto. 1989. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58: 573-581.
15. Heinrich, P. C., I. Behrmann, G. Müller-Newen, F. Schaper, and L. Graeve. 1998. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334: 297-314.
16. Murakami, M., M. Hibi, N. Nakagaw a, T. Nakagawa, K. Yasukawa, K. Yamanishi, T. Taga, and T. Kishimoto. 1993. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 260: 1808-1810.
17. Stahl, N., T. G. Boulton, T. Farruggella, N. Y. Ip, S. Davis, B. A. Witthuhn, F. W. Quelle, O. Silvennoinen, G. Barbieri, S. Pellegrini, et al. 1994. Association and activation of Jak-Tyk kinases by CNT F-LIF-OSM-IL-6 beta receptor components. Science 263: 92-95.
18. Zhong, Z., Z. Wen, and J. E. Darnell, Jr. 1994. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 264: 95-98.
19. Müllberg, J., H. Schooltink, T. Stoyan, P. C. Heinrich, and S. Rose-John. 1992. Protein kinase C activity is rate limiting for shedding of the interleukin-6 receptor. Biochem. Biophys. Res. Commun. 189: 794-800.
20. Peters M, K. H. Meyer zum Büschenfelde, and S. Rose-John., 1996. The function of the soluble IL-6 receptor in vivo. Immunol. Lett. 54, 177-184.
21. Scheller, J., A. Chalaris, C. Garbers, and S. Rose-John. 2011. ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol. 32: 380-387.
22. Briso, E. M., O. Dienz, and M. Rincon. 2008. Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells. J. Immunol. 180: 7102-7106.
23. Chalaris, A., B. Rabe, K. Paliga, H. Lange, T. Laskay, C. A. Fielding, S. A. Jones, S. Rose-John, and J. Scheller. 2007. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 110: 1748-1755.
24. Fenton, J. I., S. D. Hursting, S. N. Perkins, and N. G. Hord. 2006. Interleukin-6 production induced by leptin treatment promotes cell proliferation in an ApcMin/+ colon epithelial cell line. Carcinogenesis 27: 1507-1515.
25. Jones, S. A., S. Horiu chi, D. Novick, N. Yamamoto, and G. M. Fuller. 1998. Shedding of the soluble IL-6 receptor is triggered by Ca2+ mobilization, while basal release is predominantly the product of differential mRNA splicing in THP-1 cells. Eur. J. Immuno l. 28: 3514-3522.
26. Matthews, V., B. Schuster, S. Schütze, I. Bussmeyer, A. Ludwig, C. Hundhausen, T. Sadowski, P. Saftig, D. Hartmann, K. J. Kallen, and S. Rose-John. 2003. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J. Biol. Chem. 278: 38829-38839.
27. Booth, B. W., T. Sandifer, E. L. Martin, and L. D. Martin. 2007. IL-13-induced proliferation of airway epithelial cells: mediation by intracellular growth factor mobilization and ADAM17. Respir. Res. 8: 51.
28. Cesaro, A., A. Abakar-Mahamat, P. Brest, S. Lassalle, E. Selva, J. Filippi, X. Hé buterne, J. P. Hugot, A. Doglio, F. Galland, et al. 2009. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am. J. Physiol. G astrointest. Liver Physiol. 296: G1332-G1343.
29. Charbonneau, M., K. Harper, F. Grondin, M. Pelmus, P. P. McDonald, and C. M. Dubois. 2007. Hypoxia-inducible factor mediates hypoxic and tumor necrosis factor a-induced increases in tumor necrosis factor-A converting enzyme/ADAM17 expression by synovial cells. J. Biol. Chem. 282: 33714-33724.
30. Franchimont, N., C. Lambert, P. Huynen, C. Ribbens, B. Relic, A. Chariot, V. Bours, J. Piette, M. P. Merville, and M. Malaise. 2005. Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor a and is partially mediated by tumor necrosis factor a-converting enzyme in osteoblastlike cells. Arthritis Rheum. 52: 84-93.
31. Neurath, M. F., and S. Finotto. 2011. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev. 22: 83-89.
32. Cronstein, B. N. 2007. Interleukin-6: a key mediator of systemic and local symptoms in rheumatoid arthritis. Bull. NYU Hosp. Jt. Dis. 65(Suppl. 1): S11-S15.
33. Finotto, S., T. Eigenbrod, R. Karwot, I. Boross, A. Doganci, H. Ito, N. Nishimoto, K. Yoshizaki, T. Kishimoto, S. Rose-John, et al. 2007. Local blockade of IL-6R signaling induces lu ng CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Int. Immunol. 19: 685-693.
34. Atreya, R., J. Mudter, S. Finotto, J. Müllberg, T. Jostock, S. Wirtz, M. Schütz, B. Bartsch, M. Holtmann, C. Becker, et al. 2000. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Na t. Med. 6: 583-588.
35. Matsumoto, S., T. Hara, K. Mitsuyama, M. Yamamoto, O. Tsuruta, M. Sata, J. Scheller, S. Rose-John, S. Kado, and T. Takada. 2010. Essential roles of IL-6 tran s-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitisassociated premalignant cancer in a murine model. J. Immunol. 184: 1543-1551.
36. Müller-Newen, G., A. Küster, U. Hemmann, R. Keul, U. Horsten, A. Martens, L. Graeve, J. Wijdenes, and P. C. Heinrich. 1998. Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp13 0 on IL-6 responses. J. Immunol. 161: 6347-6355.
37. Jostock, T., J. Müllberg, S. Ozbek, R. Atreya, G. Blinn, N. Voltz, M. Fischer, M. F. Neurath, and S. Rose-John. 2001. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur. J. Biochem. 268: 160-167.
38. Hasegawa, M., S. Sato, M. Fujimoto, H. Ihn, K. Kikuchi, and K. Takehara. 1998. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis . J. Rheumatol. 25: 308-313.
39. Sato, S., M. Hasegawa, and K. Takehara. 2001. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J. Dermatol. Sci. 27: 140-146.
40. Migita, K., S. Abiru, Y. Maeda, M. Daikoku, K. Ohata, M. Nakamura, A. Komori, K. Yano, H. Yatsuhashi, K. Eguchi, and H. Ishibashi. 200 6. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum. Immunol. 67: 27-32.
41. Dai, Y., W. Zhang, J. Wen, Y. Zhang, R. E. Kellems, and Y. Xia. 2011. A2B adenosine receptor-mediated induction of IL-6 promotes CKD. J. Am. Soc. Nephrol. 22: 890-901.
42. Melé ndez, G. C., J. L. McLarty, S. P. Levick, Y. Du, J. S. Janicki, and G. L. Brower. 2010. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56: 225-231.
43. Tanaka, T., M. Narazaki, and T. Kishimoto. 2012. Therapeutic targeti ng of the interleukin-6 receptor. Annu. Rev. Pharmacol. Toxicol. 52: 199-219.
44. Ammit, A. J., L. M. Moir, B. G. Oliver, J. M. Hughes, H. Alkhouri, Q. Ge, J. K. Burgess, J. L. Black, and M . Roth. 2007. Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle. Am. J. Physiol. Lung Cell. Mol. Physiol. 292: L199-L206.
45. Zhong, H., L. Belardinelli, T. Maa, and D. Zeng. 2005. Synergy between A2B adenosine receptors and hypoxia in activating human lung fibroblasts. Am. J. Respir. Cell Mol. Biol. 32: 2-8.
46. Zhang, H., P. Neuhö fer, L. Song, B. Rabe, M. Lesina, M. U. Kurkowski, M. Treiber, T. Wartmann, S. Regné r, H. Thorlacius, et al. 2013. IL-6 transsignaling promotes pancreatitis-associated lung injury and lethality. J. Clin. Invest. 123: 1019-1031.
47. O'Donoghue, R. J., D. A. Knight, C. D. Richards, C. M. Prê le, H. L. Lau, A. G. Jarnicki, J. Jones, S. Bozinovski, R. Vlahos, S. Thiem, et al. 2012. Genetic partitioning of interleukin-6 signall ing in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol. Med. 4: 939-951.
48. Zhou, Y., D. J. Schneider, E. Morschl, L. Song, M. Pedroza, H. Karmouty-Quintana, T. Le, C. X. Sun, and M. R. Blackburn. 2011. Distinct roles for the A2B adenosine receptor in acute and chronic stages of bleomycin-induced lung injury. J. Immunol. 186: 1097-1106.
49. Swiderski, R. E., J. E. Dencoff, C. S. Floerchinger, S. D. Shapiro, and G. W. Hunninghake. 1998. Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 152: 821-828.
50. Karmouty-Quintana, H., H. Zhong, L. Acero, T. Weng, E. Melicoff, J. D. West, A. Hemnes, A. Grenz, H. K. Eltzschig, T. S. Blackwell, et al. 2012. The A2B adenosine receptor modulates pulmonar y hypertension associated with interstitial lung disease. FASEB J. 26: 2546-2557.
51. Baran, C. P., J. M. Opalek, S. McMaken, C. A. Newland, J. M. O'Brien, Jr., M. G. Hunter, B. D. Bringardner, M. M. Monick, D. R. Brigstock, P. C. Stromberg, et al. 2007. Important roles for macrophage colony-stimulating factor, CC chemokine ligand 2, and mononuclear phagocytes in the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 176: 78-89.
52. Chua, F., J. Gauldie, and G. J. Laurent. 2005. Pulmonary fibrosis: searching for model answers. Am. J. Respir. Cell Mol. Biol. 33: 9-13.
53. Murray, L. A., R. Rosada, A. P. Moreira, A. Joshi, M. S. Kramer, D. P. Hesson, R. L. Argentieri, S. Mathai, M. Gulati, E. L. Herzog, and C. M. Hogaboam. 2010. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PLoS ONE 5: e9683.
54. Trujillo, G., E. C. O'Connor, S. L. Kunkel, and C. M. Hogaboam. 2008. A novel mechanism fo r CCR4 in the regulation of macrophage activation in bleomycininduced pulmonary fibrosis. Am. J. Pathol. 172: 1209-1221.
55. Pechkovsky, D. V., A. Prasse, F. Kollert, K. M. Engel, J. Dentler, W. Luttmann, K. Friedrich, J. Müller-Quernheim, and G. Zissel. 2010. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clin. Immunol. 137: 89-101.
56. Murray, L. A., Q. Chen, M. S. Kramer, D. P. Hesson, R. L. Argentieri, X. Peng, M. Gulati, R. J. Homer, T. Russell, N. van Rooijen, et al. 2011. TGF-b driven lung fibrosis is macrophage dependent a nd blocked by serum amyloid P. Int. J. Biochem. Cell Biol. 43: 154-162.
57. Collins, S. L., Y. Chan-Li, R. W. Hallowell, J. D. Powell, and M. R. Horton. 2012. Pulmonary vaccination as a novel treatment for lung fibrosis. PLoS ONE 7: e31299.
58. Modolell, M., I. M. Corraliza, F. Link, G. Soler, and K. Eichmann. 1995. Reciprocal regulation of the nitric oxide synthase/arginase balance in mouse b one marrow-derived macrophages by TH1 and TH2 cytokines. Eur. J. Immunol. 25: 1101-1104.
59. Stein, M., S. Keshav, N. Harris, and S. Gordon. 1992. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176: 287-292.
60. Mosser, D. M., and X. Zhang. 2008. Activation of murine macrophages. Curr. Protoc. Immunol. 83: 1421-1428.
61. Wynn, T. A. 2003. IL-13 effector functions. Annu. Rev. Immunol. 21: 425-456.
62. Althoff, K., P. Reddy, N. Voltz, S. Rose-John, and J. Mullberg. 2000. Shedding of interleukin-6 receptor and tumor necrosis factor a. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins. Eur. J. Biochem. 267: 2624-2631.
63. Rennard S.I.,R.G. Crystal 1982, Fibronectin in human bronchopulmonary lavage fluid. Elevation in patients with interstitial lung disease, J. Clin. Invest., 69, 113-122.
64. Crosby, L. M., and C. M.Waters. 2010. Epithelial repair mechanisms in the lung. Am. J. Physiol. Lung Cell. Mol. Physiol. 298: L715-L731.
65. White, E. S., F. E. Baralle, and A. F. Muro. 2008. New insights into form and function of fibronectin splice variants. J. Pathol. 216: 1-14.
66. White, E. S., and A. F. Muro. 2011. Fibronectin splice variants: understandin g their multiple roles in health and disease using engineered mouse models. IUBMB Life 63: 538-546.
67. Knight, D., S. E. Mutsaers, and C. M. Prê le. 2011. STAT3 in tissue fibrosis: is there a role in the lung? Pulm. Pharmacol. Ther. 24: 193-198.
68. Prê le, C. M., E. Yao, R. J. O'Donoghue, S. E. Mutsaers, and D. A. Knight. 2012. STAT3: a central mediator of pulmonary fibrosis? Proc. Am. Thorac. Soc. 9: 177-182.
69. Pechkovsky, D. V., C. M. Prêle, J. Wong, C. M. Hogaboam, R. J. McAnulty, G. J. Laurent, S. S. Zhang, M. Selman, S. E. Mutsaers, and D. A. Knight. 2012. STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF. Am. J. Pathol. 180: 1398-1412.
70. Garbers, C., N. Jä nner, A. Chalaris, M. L. Moss, D. M. Floss, D. Meyer, F. Koch-Nolte, S. Rose-John, and J. Scheller. 2011. Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J. Biol. Chem. 286: 14804-14811.
71. Lo Re, S., D. Lison, and F. Huaux. 2013. CD4+ T lymphocytes in lung fibrosis: diverse subsets, diverse functions. J. Leukoc. Biol. 93: 499-510.
72. Nuovo , G. J., J. S. Hagood, C. M. Magro, N. Chin, R. Kapil, L. Davis, C. B. Marsh, and V. A. Folcik. 2012. The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod. Pathol. 25: 416-433.
73. Drucker, C., B. Rabe, A. Chalaris, E. Schulz, J. Scheller, and S. Rose-John. 2009. Interleukin-6 trans-signaling regulates glycogen consumption after D-galactosamineinduced l iver damage. J. Interferon Cytokine Res. 29: 711-718.
74. Ray, S., X. Ju, H. Sun, C. C. Finnerty, D. N. Herndon, and A. R. Brasier. 2013. The IL-6 trans-signaling-STAT3 pathway mediates ECM and cellular proliferation in fibroblasts from hypertrophic scar. J. Invest. Dermatol. 133: 1212-1220.
75. Moodley, Y. P., A. K. Scaffidi, N. L. Misso, C. Keerthisingam, R. J. McAnulty, G. J. Laurent, S. E. Mutsaers, P. J. Thompson, and D. A. Knight. 2003. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gp130-mediated cell signaling and proliferation. Am. J. Pathol. 163: 345-354.